J&J inks a $1.15B discovery deal with PeptiDream; Medivir plots PhIII HDAC program

→ Tokyo-based PeptiDream has struck a discovery deal with J&J worth up to $1.15 billion. In the deal PeptiDream will use its platform tech to “identify macrocyclic/constrained peptides against multiple metabolic and cardiovascular targets of interest selected by Janssen, and to optimize hit peptides into therapeutic peptides or small molecule products.”

→ Sweden’s Medivir says that they’ve gathered some positive results from a Phase II study of their HDAC inhibitor remetinostat for cutaneous T-cell lymphoma. Early stage patients in the 1% remetinostat gel BID arm had the highest proportion of confirmed responses (8/20, 40%), including one complete response. The biotech says it is now planning a pivotal Phase III program.

→ Galenica Sante has now completed its IPO, separating from Vifor Pharma Group, which will now focus entirely on the pharmaceuticals side of the business as Galenica hives off health and beauty.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Technical Operations Manager
Molecular Templates Austin, TX
Senior Director, Global Commercial Strategy, Rare Disease
Govig BioPharma/Aeglea BioTherapeutics Austin, TX
Senior Manager, Sales & Client Development
Aldevron Boston or San Francisco
Scientist, Cellular Immunology
Codiak BioSciences Cambridge, MA
Director of Quality Assurance
Aldevron Fargo, ND
Principal Scientist, Immuno-Oncology (Inflammation)
Codiak BioSciences Cambridge, MA

Visit Endpoints Careers ->